LH-RH agonist (Buserelin): treatment of endometriosis

U Cirkel, Karl-Werner Schweppe, K W Schweppe, H Ochs, J P Hanker, H P Schneider, H. P. G. Schneider
Archives of gynecology and obstetrics · 1989 · vol. 246(3) , pp. 139–151 · doi:10.1007/bf00934075 · PMID:2515811 · W2316994966
article OA: closed CC0 ⤵ 4 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

Buserelin treatment of endometriosis resulted in implant regression and indicated anovulatory cycles with reduced estradiol and progesterone, while favorably affecting HDL cholesterol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated intranasal LH-RH (GnRH) agonist buserelin in 64 patients with histologically verified endometriosis treated for 6 months at 900 μg/day. Follow-up surgery reported regression of endometriotic implants in 73% of cases, with adhesions appearing unaffected, and among 45 patients with prior infertility the uncorrected pregnancy rate was 40% while histology-confirmed recurrence was 9.4%. Endocrine testing showed marked estradiol suppression and progesterone decline consistent with anovulatory cycles, with decreased LH and prolactin but unchanged FSH; limited endocrine/bone-medicine markers (calcitonin and PTH fragments) and multiple metabolic panels showed no negative metabolic effects, while HDL increased and most subjective complaints were attributed to hypoestrogenism. This paper is centrally about endometriosis — evaluating buserelin’s effects on implant regression, recurrence, endocrine suppression, and side effects in treated patients.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Uterine Neoplasms Buserelin Buserelin Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
unpaywall
last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0 · commercial use OK